Bile acid, neutral sterol and faecal fat excretion was studied over a period of 9 weeks in a group of 16 healthy subjects before, during and after administration of fenfluramine. Statistical analysis revealed a significant increase in bile acid excretion during the drug phase (P<0.02); and during recovery period of 3 weeks (P< 0-05). Faecal neutral sterol, as the total of coprostanol and cholesterol elimination was also enhanced after fenfluramine. Coprostanol was replaced by cholesterol in 12 subjects. Faecal fat was studied in 6 subjects, the excretion increased during the drug phase (P< 005), and remained elevated during the post-drug period (P< 001). The composition of the bile acids remained unaltered in all the subjects except 3 who had a fenfluramine-induced watery diarrhoea; and these excreted chenodeoxy and cholic together with smaller amounts of secondary bile acids. A higher excretion of bile acids was found in the 8 overweight subjects (P<0.01) before ministration of fenfluramine.
Introduction
Obesity presents a major nutritional and medical problem. Its complications are well documented such as increased morbidity and mortality due to cardiovascular disorders, hypertension, diabetes and cholelithiasis. Dietary restriction on its own by personal effort is not always effective in the management of simple, exogenous obesity. Controlled trials on the use of appetite suppressants such as amphetamines have shown a variety ofundesirable side effects including central nervous stimulation, addiction, toxicity, euphoria and even ineffectiveness. The use of amphetamines has been discouraged but fenfluramine, an analogue of amphetamine, has become widely used as an anti-obesity agent devoid of central nervous stimulation (Munro, Seaton and Duncan, 1966; Le Douarec and Niven, 1970) . There are reports of its beneficial effects on hyperlipidaemia (Pawan, 1969; Bliss, Kirk and Newall, 1972) , on hypercholesterolaemia (Tomlinson, Lines and Greenfield, 1975) , and on hyperglycaemia (Turtle, 1972) . However it has been reported that some patients on the drug complain of frequency of bowel motions amounting to diarrhoea. The incidence of diarrhoea reported by Munro et al. (1966) , Hollingsworth and Amatruda (1969) and Sedgwick (1972) was 40, 44 and 67%/ respectively. The cause of this diarrhoea consecutive to the treatment with fenfluramine is obscure. No direct correlation has been reported between the onset of diarrhoea and serum levels of fenfluramine. Dietetic survey in people with frequency of bowel motions suggest an interaction between nutrients (fish) and the drug. Studies by Duhault and Verdavainne (1967) suggested that diarrhoea may be related to the decreased absorption of triglycerides in the intestinal tract, to the release of serotonin or to the alteration in gut motility. Some of these views were supported by Garattini (1971) (1975) revealed that the apparent digestibility of fat in healthy students was unimpaired, and there was no evidence of reduction of intestinal fat absorption.
One line of study which interests the present authors is the examination of the effect of fenfluramine on bile acid metabolism, and in this investigation they set out to examine the effect of fenfluramine on total faecal bile acid and neutral sterol excretion in healthy subjects before, during and after ad- (Weijers and Van de Kamer, 1953) .
Analysis of bile acids and neutral sterols
The freeze-dried samples of faeces were extracted using a method based on that of Evrard and Janssen (1968) , with subsequent analysis of bile acids and neutral sterols by gas chromatography (Eneroth, Hellstrom and Sjovall, 1968) . The degree of conjugation of bile acids was determined using thin layer chromatography (Huang and Nichols, 1975) .
Statistical analysis
Student's t-test was used to compare the bile acid and neutral sterol excretion in the 16 subjects during the 3 phases of the study.
The reproducibility of bile acid analysis was studied in one individual over the 9-week experimental period. The coefficient of variation of replicate analysis (n=15) was 7-6% during the predrug period. The mean faecal bile acid excretion during this period was 9.3±+0.4 mg/g dry weight faeces (range 8.9-9.9). After the administration of the drug the coefficient of variation was 9.8% and the mean bile acid excretion was 110 0-5 mg/g dry weight faeces (range 10-3-11-7).
Results

Bile acids
The mean bile acid excretion for the 16 subjects during the pre-drug period was 9.3 ± 3-1 mg/g dry weight faeces compared to 12.1 ± 4.5 mg/g dry weight during the drug period (P<0-02). The bile acid excretion remained elevated after the withdrawal of fenfluramine (11-6 + 3.4 mg/g dry weight) (P<0O05). There was no statistically significant difference between the excretion during the drug phase and the post-drug phase (12-1 + 4-5 mg/g dry weight compared to 11-6+3 4 mg/g dry weight).
This implies that the drug effect persisted for at least 3 weeks after the withdrawal of fenfluramine.
Bile acid excretion in the subjects with normal body weight ( Fig. la) was compared with the excretion in the overweight subjects ( Fig. 1 b) . During the period before the administration of fenfluramine the bile acid excretion in the overweight subjects (10-8 ± 3.8 mg/g dry weight) is significantly higher (P<0-01) than the bile acid excretion in those of normal weight (7.7 + 0.7 mg/g dry weight). The excretion remained high in the overweight subjects (137 ±+5-3 compared to 10.5+3±1 mg/g dry weight) during the drug period (P<0O01); and also during the post-drug period (12.9±3.8 mg/g dry weight compared to 10-3+ 2.6 mg/g dry weight; P<O001).
In 7 subjects bile acid excretion reached a peak by the end of the second week on the drug. In 4 subjects excretion dropped during the first week and then increased in the second and third week of medication. Three subjects had diarrhoea, and limited quantitative data only were obtainable because of the problem of 24-hr faecal collection in these subjects. 
Neutral sterols
The neutral sterol excretion, as the total of coprostanol and cholesterol, also indicated a similar increase. The mean neutral sterol excretion for the 16 subjects was 167 + 49 mg/g dry weight during the pre-drug period. The excretion increased to 23-3 ±86 mg/g dry weight during the drug period (P<0-02). The excretion remained elevated at 241 + 9-0 mg/g dry weight during the post-drug period (P<0-01).
Total faecal steroids (bile acids and neutral sterols)
The mean excretion of total faecal steroids as the sum of bile acids and neutral sterols was 260 + 70 mg/g dry weight during the pre-drug period. The excretion increased to 352 ± 10-7 mg/g dry weight during the drug period (P<0-01), and to 36-7 ±11-5 mg/g dry weight during the post-drug period (P<0-01) ( Fig. la and b) .
The excretion of total faecal steroids in the overweight subjects was 29-8 + 7-6 mg/g dry weight as compared with 22-1 +39 mg/g dry weight in the subjects of normal weight. This failed to reach the 5% level of significance.
Faecal fat
The mean faecal fat excretion in 6 subjects during the pre-drug period was 2-61 ± 0-39 g/day. There was a significant increase in the excretion during the drug period (3-86+ 109 g/day; P<0O05): and also during the post-drug period (3.14+0-46 g/day; P<0-01), (Fig. 2) Table 1 .
The subjects with fenfluramine-induced diarrhoea excreted increased amounts of primary bile acids, i.e. chenodeoxycholic (3cc, 7a) and cholic acid (Tri-OH) (Fig. 3) . In these subjects the excretion of primary bile acids increased from 2-8 + 1-5 mg/g dry weight, during the period before the administration of fenfluramine, to 7-3 + 5-6 mg/g dry weight during the drug period (P<0-05).
Thin layer chromatography of faecal bile acids revealed that bile acids excreted before and after the administration of fenfluramine were in the unconjugated form (Fig. 4) if the sensitivity of the TLC system is taken into consideration.
Neutral sterols
The analysis of faecal neutral sterols revealed that coprostanol was the major neutral sterol excreted during the pre-drug period (Fig. 5) Mitchell and Eastwood (1972) in patients with ileal dysfunction.
Studies carried out by Kirwan et al. (1975) have demonstrated a direct relationship between the colonic motility and faecal bile acid excretion. They reported chenodeoxycholic to be the principal factor The pattern of neutral sterols in the faeces was altered after the administration of fenfluramine.
Normally coprostanol is the predominant neutral sterol with small amounts of cholestanol and plant sterols. These neutral sterols are metabolites formed from cholesterol in the gastrointestinal tract by the action of intestinal micro-organisms (Eneroth, Hellstrom and Ryhage, 1964) . These metabolites are poorly absorbed from the gut and, therefore, constitute major neutral sterols in normal faeces. This form of pattern of neutral sterols was observed in the present study during the pre-drug period.
After the administration of fenfluramine the excretion of coprostanol was replaced by cholesterol in the faeces (Fig. 5) . Similar observation was made by Meihoff and Kern (1968) in patients with mannitol-induced diarrhoea. They reported a decrease in intestinal transit from a mean of 26 hr before the study to 4-6 hr during the period of diarrhoea and demonstrated alterations in faecal steroid patterns together with an increase in bile acids, neutral sterols and faecal fat excretion in their subjects. They suggested that rapid transit through the gastrointestinal tract was the major factor which decreases the normal absorption of bile acids, neutral sterols and faecal fat, hence the excretion of these increases. Bile acid excretion pattern in the overweight subjects Bile acid excretion was significantly higher in the overweight subjects. This observation is in agreement with the findings of Miettinen (1971) who reported a higher bile acid and neutral sterol excretion in obese normolipidaemic subjects as compared to non-obese normolipidaemic subjects and demonstrated that the greater the body weight the higher was the excretion of bile acids and neutral sterols. The value of 7.7 ±0-7 mg/g dry weight for bile acid excretion in the subjects with normal weight is similar to that of 6.13 mg/g dry weight for 20 subjects reported by Aries et al. (1971) and that of 8.72 mg/g dry weight for 5 normals reported by Evrard and Janssen (1968) . Similar observations were also reported by Nestel and Hunter (1974) in studies of bile acid excretion in the overweight.
The pattern of bile acid excretion in the overweight subjects compared to those of normal weight differed only in the levels of cholic acid excretion.
This was 5% by weight of the bile acid excretion in the over-weight group compared with 2% in the normal group (P<0-05).
Bile acid and neutral sterol excretion (cholesterollowering effect) Results of the present study reveal a significant increase in excretion of bile acids, neutral sterols and faecal fat after fenfluramine. In studies of cholesterol production in obesity Miettinen (1971) Miettinen (1973) also reported that the removal of cholesterol as bile acids in the faeces is the primary factor which determines the level of serum cholesterol. Rubulis et al. (1970) studied the effect of neomycin and colchicine on serum cholesterol and reported an increase in excretion of bile acids, neutral sterols and faecal fat. Coincident with these changes there was a significant decrease in serum cholesterol and lipids.
Therefore the observation of increased excretion of bile acids and neutral sterols after fenfluramine suggests an increased catabolism of cholesterol and possibly a decrease in the level of serum cholesterol pool.
The lipid-lowering effect of fenfluramine has been reported to be related to the inhibition exerted by the drug on gastric and intestinal motility (Garattini, 1971) . The lipid-lowering effect ofthe drug is of particular interest in the obese patient where endogenous production of cholesterol is normally increased (Miettinen, 1971 ). The present results are consistent with the previous observation made from this laboratory, that fenfluramine caused a small but significant decrease in serum cholesterol (Bliss et al., 1972) . The cholesterol-lowering effect of fenfluramine was also observed by Dannenburg and Chremos (1971) , and by Tomlinson et al. (1975) who also reported a decrease of 14% in the level of serum cholesterol in hypercholesterolaemic patients within 2 weeks.
From their study it appears to the authors that the increased faecal bile acid and neutral sterol excretion observed after administration of fenfluramine suggests enhanced removal of cholesterol. This could be beneficial in obesity and related metabolic disorders. 
